Kinney E L, Caldwell J W
Reed Institute, Miami, Florida.
Angiology. 1990 Jul;41(7):573-6. doi: 10.1177/000331979004100711.
Whereas the total mortality rate for sarcoidosis is 0.2 per 100,000, the prognosis, when the heart is involved, is very much worse. The authors used the difference in mortality rate to infer whether thallium 201 myocardial perfusion scan abnormalities correspond to myocardial sarcoid by making the simplifying assumption that if they do, then patients with abnormal scans will be found to have a death rate similar to patients with sarcoid heart disease. The authors therefore analyzed complete survival data on 52 sarcoid patients without cardiac symptoms an average of eighty-nine months after they had been scanned as part of a protocol. By use of survival analysis (the Cox proportional hazards model), the only variable that was significantly associated with survival was age. The patients' scan pattern, treatment status, gender, and race were not significantly related to survival. The authors conclude that thallium myocardial perfusion scans cannot reliably be used to diagnose sarcoid heart disease in sarcoid patients without cardiac symptoms.
结节病的总死亡率为每10万人中有0.2人，然而，当心脏受累时，预后要差得多。作者通过做出一个简化假设来利用死亡率差异推断铊201心肌灌注扫描异常是否与心肌结节病相对应，即如果两者对应，那么扫描异常的患者的死亡率将与结节性心脏病患者相似。因此，作者分析了52名无心脏症状的结节病患者的完整生存数据，这些患者在作为一项研究方案的一部分进行扫描后的平均随访时间为89个月。通过生存分析（Cox比例风险模型），唯一与生存显著相关的变量是年龄。患者的扫描模式、治疗状态、性别和种族与生存无显著相关性。作者得出结论，铊心肌灌注扫描不能可靠地用于诊断无心脏症状的结节病患者的结节性心脏病。
